1. Lead Researcher: Jennifer Soung, M.D.

2. Study Title: A Phase 3b, Multicenter, Randomized, Placebo-Controlled, Double Blind, Double-Dummy, Study of the Efficacy and Safety of Apremilast (CC-10004), Etanercept, and Placebo, in Subjects with Moderate to Severe Plaque Psoriasis

3. Purpose of Study (e.g., to evaluate a new drug for breast cancer): The purpose of this research study is to find out more about apremilast in people with psoriasis.

4. Eligibility (e.g., adults on medication for high blood pressure; diabetic patients on insulin; normal, healthy adults; etc.): Adults who have been diagnosed with psoriasis

5. Location (if other than UCIMC):
Dermatology Research Center, 843 Health Sciences Road Room 1001, Irvine, CA 92697

6. Time Commitment (e.g., three one-hour long visits in three weeks): This study includes 27 visits and takes about 28 hours over a period of approximately 2 years. You will be seen weekly from Baseline to Week 17. You will then have visits at Weeks 20, 24, 32, 40, 52, 78 and 104. You will also have a Post-treatment Observational Follow-up Visit at 4 weeks after your last dose of study drug.

7. Anticipated Benefits (if any): Taking part in this study may or may not make your health better. While researchers hope that apremilast will be better than the standard (usual) treatment, there is no proof of this yet. If apremilast proves to treat your condition more effectively or with less side effects than the standard treatment, you may benefit from participating in the study, but this cannot be guaranteed.

8. Compensation (if any): You may be compensated up to $910.

9. Contact Name, UCI Department, Phone Number and E-mail:
Brian Swasdibutra
UCI Dermatology Research
949-824-7103
bswasdib@uci.edu